Supplementary Figure S6 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

crossref(2024)

Cited 0|Views10
No score
Abstract

Comparison between pathologic response, radiologic response, and time of neoadjuvant period.

More
Translated text
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined